S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)
S&P 500   4,550.58 (-0.09%)
DOW   35,430.42 (+0.04%)
QQQ   389.81 (-0.10%)
AAPL   189.37 (-0.54%)
MSFT   378.85 (-1.01%)
META   332.20 (-2.00%)
GOOGL   134.99 (-1.61%)
AMZN   146.32 (-0.48%)
TSLA   244.14 (-1.05%)
NVDA   481.40 (+0.67%)
NIO   7.18 (-0.42%)
BABA   74.67 (-2.70%)
AMD   123.85 (+1.51%)
T   16.30 (+0.74%)
F   10.59 (+2.12%)
MU   76.69 (+0.75%)
CGC   0.56 (+3.65%)
GE   118.86 (+0.01%)
DIS   92.50 (+0.00%)
AMC   7.17 (+7.01%)
PFE   30.08 (+1.31%)
PYPL   57.97 (-0.86%)
XOM   102.34 (-1.50%)

Ginkgo Bioworks Stock Price, News & Analysis (NYSE:DNA)

$1.39
-0.05 (-3.47%)
(As of 05:11 PM ET)
Compare
Today's Range
$1.39
$1.55
50-Day Range
$1.26
$1.83
52-Week Range
$1.12
$2.55
Volume
20.76 million shs
Average Volume
20.66 million shs
Market Capitalization
$2.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25

Ginkgo Bioworks MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.75 Rating Score
Upside/​Downside
55.7% Upside
$2.25 Price Target
Short Interest
Bearish
17.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.17mentions of Ginkgo Bioworks in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$22.72 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.37) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

648th out of 949 stocks

Biological Products, Except Diagnostic Industry

106th out of 161 stocks


DNA stock logo

About Ginkgo Bioworks Stock (NYSE:DNA)

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

DNA Stock Price History

DNA Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Ginkgo Bioworks (NYSE:DNA) Stock Price Up 5.8%
Where Will Ginkgo Bioworks Be in 5 Years?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Ginkgo Bioworks: A Long Way To Go
Ginkgo Bioworks: More Revenue Issues
Preview: Ginkgo Bioworks Holdings's Earnings
Porter's 5 Forces Suggest That Ginkgo Is A Buy
See More Headlines
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,292
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.25
High Stock Price Target
$3.00
Low Stock Price Target
$1.25
Potential Upside/Downside
+55.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.75
Research Coverage
4 Analysts

Profitability

Net Income
$-2,104,930,000.00
Net Margins
-272.30%
Pretax Margin
-275.85%

Debt

Sales & Book Value

Annual Sales
$477.71 million
Book Value
$0.59 per share

Miscellaneous

Outstanding Shares
2,118,440,000
Free Float
1,799,612,000
Market Cap
$3.07 billion
Optionable
Optionable
Beta
1.31
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














DNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" DNA shares.
View DNA analyst ratings
or view top-rated stocks.

What is Ginkgo Bioworks' stock price target for 2024?

4 brokerages have issued 1 year target prices for Ginkgo Bioworks' shares. Their DNA share price targets range from $1.25 to $3.00. On average, they predict the company's share price to reach $2.25 in the next year. This suggests a possible upside of 59.5% from the stock's current price.
View analysts price targets for DNA
or view top-rated stocks among Wall Street analysts.

How have DNA shares performed in 2023?

Ginkgo Bioworks' stock was trading at $1.69 at the start of the year. Since then, DNA stock has decreased by 16.6% and is now trading at $1.4103.
View the best growth stocks for 2023 here
.

Are investors shorting Ginkgo Bioworks?

Ginkgo Bioworks saw a decline in short interest in November. As of November 15th, there was short interest totaling 222,910,000 shares, a decline of 5.5% from the October 31st total of 235,940,000 shares. Based on an average daily volume of 19,520,000 shares, the days-to-cover ratio is currently 11.4 days. Approximately 17.2% of the shares of the stock are short sold.
View Ginkgo Bioworks' Short Interest
.

When is Ginkgo Bioworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our DNA earnings forecast
.

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (11.38%), ARK Investment Management LLC (8.68%), Sumitomo Mitsui Trust Holdings Inc. (2.80%), Schroder Investment Management Group (0.35%), Charles Schwab Investment Management Inc. (0.35%) and Welch & Forbes LLC (0.33%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends
.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:DNA) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -